Iris International Seeks Reimbursement For Its Prostate Molecular Dx

The firm, soon to be acquired by Danaher, is pursuing a major data collection effort to gain reimbursement for its ultrasensitive prostate cancer assay, following a 300-patient trial to support 510(k) clearance.